PuSH - Publication Server of Helmholtz Zentrum München: Bridging the gap between science and clinical efficacy: Physiology, imaging, and modeling of aerosols in the lung.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Darquenne, C.* ; Fleming, J.S.* ; Katz, I.* ; Martin, A.R.* ; Schroeter, J.* ; Usmani, O.S.* ; Venegas, J.* ; Schmid, O.

Bridging the gap between science and clinical efficacy: Physiology, imaging, and modeling of aerosols in the lung.

J. Aerosol Med. Pulm. Drug Deliv. 29, 107-126 (2016)

Postprint

DOI

	Open Access Green

Abstract
Metrics
Extra information

Development of a new drug for the treatment of lung disease is a complex and time consuming process involving numerous disciplines of basic and applied sciences. During the 2015 Congress of the International Society for Aerosols in Medicine, a group of experts including aerosol scientists, physiologists, modelers, imagers, and clinicians participated in a workshop aiming at bridging the gap between basic research and clinical efficacy of inhaled drugs. This publication summarizes the current consensus on the topic. It begins with a short description of basic concepts of aerosol transport and a discussion on targeting strategies of inhaled aerosols to the lungs. It is followed by a description of both computational and biological lung models, and the use of imaging techniques to determine aerosol deposition distribution (ADD) in the lung. Finally, the importance of ADD to clinical efficacy is discussed. Several gaps were identified between basic science and clinical efficacy. One gap between scientific research aimed at predicting, controlling, and measuring ADD and the clinical use of inhaled aerosols is the considerable challenge of obtaining, in a single study, accurate information describing the optimal lung regions to be targeted, the effectiveness of targeting determined from ADD, and some measure of the drug's effectiveness. Other identified gaps were the language and methodology barriers that exist among disciplines, along with the significant regulatory hurdles that need to be overcome for novel drugs and/or therapies to reach the marketplace and benefit the patient. Despite these gaps, much progress has been made in recent years to improve clinical efficacy of inhaled drugs. Also, the recent efforts by many funding agencies and industry to support multidisciplinary networks including basic science researchers, R&D scientists, and clinicians will go a long way to further reduce the gap between science and clinical efficacy.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Aerosol Deposition Distribution ; Biological Lung Models ; In-silico Lung Modeling ; Pet ; Spect; Obstructive Pulmonary-disease; Human Respiratory-tract; In-vitro; Particle Deposition; Drug-delivery; Helium-oxygen; Regional Deposition; Gamma-scintigraphy; Inhaled Particles; Small Airways

ISSN (print) / ISBN 0894-2684

e-ISSN 1557-9026

Journal Journal of Aerosol Medicine and Pulmonary Drug Delivery

Quellenangaben Volume: 29, Issue: 2, Pages: 107-126

Publisher Mary Ann Liebert

Publishing Place New Rochelle

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Lung Health and Immunity (LHI)